Industrial Synthesis Route Methyl 2-Oxoindoline-6-Carboxylate
- Optimized Acylation: Achieves reaction yields exceeding 84% using toluene and acetic anhydride.
- High Specifications: Delivers industrial purity greater than 99% with controlled impurity profiles.
- Scalable Manufacturing: Validated process for scale-up production from grams to multi-kilogram batches.
Methyl 2-Oxoindoline-6-carboxylate, identified by CAS Number 14192-26-8, serves as a critical pharmaceutical intermediate in the synthesis of kinase inhibitors, specifically within the production pipeline for Nintedanib. As demand for anti-fibrotic and oncology therapeutics grows, the requirement for a robust, scalable, and high-purity synthesis route becomes paramount for supply chain stability. At NINGBO INNO PHARMCHEM CO.,LTD., we specialize in the manufacturing of complex heterocyclic compounds, ensuring that every batch meets stringent quality controls required for downstream API synthesis.
This technical overview details the optimized manufacturing process, impurity control strategies, and commercial considerations for procuring this key indoline derivative. Understanding the chemical nuances of this intermediate allows procurement managers and process chemists to validate supplier capabilities effectively.
Optimized Reaction Conditions for High Yield Manufacturing
The core of the manufacturing process involves the precise acylation of the indoline core. Historical data and process optimization studies indicate that avoiding high-toxicity reagents, such as chloroacetic anhydride, significantly improves the safety profile and environmental compliance of the production facility. Instead, the preferred industrial method utilizes acetic anhydride as the acylating agent in a toluene solvent system.
The reaction is typically conducted at elevated temperatures between 100°C and 110°C. Maintaining this thermal window is critical for maximizing acylation efficiency while minimizing the formation of undesired byproducts. Process data demonstrates that operating within this range allows for reaction yields consistently above 84%, even when transitioning from laboratory scale to scale-up production environments.
Following the reaction, the crude product undergoes a rigorous purification sequence. Cooling crystallization filtration is performed at 0°C to 5°C to precipitate the solid product. The filter cake is subsequently washed with organic solvents such as methanol or acetonitrile to remove residual starting materials and soluble impurities. This step is vital for achieving the required industrial purity specifications.
Impurity Control and Quality Assurance
In the synthesis of methyl 2-oxo-1,3-dihydroindole-6-carboxylate, impurity profiling is a key differentiator between standard chemical suppliers and top-tier manufacturers. The primary impurities of concern include unreacted starting materials and over-acylated byproducts. Advanced manufacturing protocols ensure that the maximum single impurity remains below 0.5%, with total purity exceeding 99% as verified by High-Performance Liquid Chromatography (HPLC).
Quality assurance protocols also include comprehensive structural verification using Nuclear Magnetic Resonance (1H-NMR) and Liquid Chromatography-Mass Spectrometry (LC-MS). These analytical techniques confirm the molecular structure and ensure that the Methyl oxindole-6-carboxylate provided matches the theoretical specifications required for subsequent condensation reactions.
| Parameter | Specification | Analytical Method |
|---|---|---|
| CAS Number | 14192-26-8 | N/A |
| Molecular Formula | C10H9NO3 | N/A |
| Molecular Weight | 191.18 g/mol | N/A |
| Purity (HPLC) | > 99.0% | Area Normalization |
| Single Impurity | < 0.5% | Area Normalization |
| Appearance | Off-white to Pale Yellow Solid | Visual |
| Melting Point | 184-190°C | DSC / Capillary |
Commercial Viability and Bulk Procurement
For pharmaceutical companies scaling toward commercial API production, the stability of the bulk price and supply consistency are as important as chemical specifications. Volatility in raw material costs, particularly for specialized solvents like orthobenzoates and acetic anhydride, can impact the final cost of goods. Established manufacturers mitigate this through long-term supplier contracts and efficient solvent recovery systems.
When sourcing high-purity Methyl 2-Oxoindoline-6-carboxylate, buyers should prioritize vendors who can provide comprehensive documentation, including Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS). Compliance with GMP standards is often required for intermediates entering the final stages of drug substance manufacturing.
NINGBO INNO PHARMCHEM CO.,LTD. maintains a robust supply chain capable of supporting multi-kilogram orders with prompt delivery schedules. Our facility is equipped to handle custom synthesis requests, allowing clients to tailor specifications such as particle size or packaging requirements to fit their specific process needs.
Downstream Application and Process Integration
The utility of this intermediate extends into the condensation reactions required to form the final kinase inhibitor structure. The high purity of the indoline derivative ensures that subsequent steps, such as condensation with orthobenzoates and final deprotection, proceed with minimal interference. Residual impurities from the intermediate stage can propagate through the synthesis tree, complicating purification at the API stage and reducing overall yield.
By securing a high-quality intermediate, process chemists can optimize downstream reaction conditions, such as solvent selection (e.g., acetonitrile vs. toluene) and base selection (e.g., potassium hydroxide vs. sodium methoxide), with greater confidence. This reliability reduces the risk of batch failures and accelerates the timeline from clinical trials to market approval.
Conclusion
The industrial production of Methyl 2-Oxoindoline-6-carboxylate requires a delicate balance of chemical precision and manufacturing scalability. Through optimized acylation protocols and rigorous impurity control, it is possible to achieve yields exceeding 84% with purity levels suitable for pharmaceutical applications. Partnering with a dedicated manufacturer ensures access to consistent quality, technical support, and reliable supply chains essential for modern drug development.